Pancreatic cancer-Associated retinoblastoma 1 dysfunction enables TGF-?beta;?to promote proliferation

A. Jesse Gore, Samantha L. Deitz, Lakshmi Reddy Palam, Kelly E. Craven, Murray Korc

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is often associated with overexpression of TGF-?. Given its tumor suppressor functions, it is unclear whether TGF-is a valid therapeutic target for PDAC. Here, we found that proliferating pancreatic cancer cells (PCCs) from human PDAC patients and multiple murine models of PDAC (mPDAC) often exhibit abundant levels of phosphorylated retinoblastoma 1 (RB) and Smad2. TGF-?1 treatment enhanced proliferation of PCCs isolated from KrasG12D-driven mPDAC that lacked RB (KRC cells). This mitogenic effect was abrogated by pharmacological inhibition of type I TGF-receptor kinase, combined inhibition of MEK/Src or MEK/PI3K, and restoration of RB expression. TGF-?1 promoted epithelial-to-mesenchymal transition (EMT), invasion, Smad2/3 phosphorylation, Src activation, Wnt reporter activity, and Smad-dependent upregulation of Wnt7b in KRC cells. Importantly, TGF-?1-induced mitogenesis was markedly attenuated by inhibition of Wnt secretion. In an in vivo syngeneic orthotopic model, inhibition of TGF-signaling suppressed KRC cell proliferation, tumor growth, stroma formation, EMT, metastasis, ascites formation, and Wnt7b expression, and markedly prolonged survival. Together, these data indicate that RB dysfunction converts TGF-to a mitogen that activates known oncogenic signaling pathways and upregulates Wnt7b, which synergize to promote PCC invasion, survival, and mitogenesis. Furthermore, this study suggests that concomitantly targeting TGF-And Wnt7b signaling in PDAC may disrupt these aberrant pathways, which warrants further evaluation in preclinical models.

Original languageEnglish
Pages (from-to)338-352
Number of pages15
JournalJournal of Clinical Investigation
Volume124
Issue number1
DOIs
StatePublished - Jan 2 2014

Fingerprint

Retinoblastoma
Pancreatic Neoplasms
Adenocarcinoma
Epithelial-Mesenchymal Transition
Mitogen-Activated Protein Kinase Kinases
Up-Regulation
Phosphatidylinositol 3-Kinases
Mitogens
Ascites
Neoplasms
Cell Survival
Phosphotransferases
Phosphorylation
Cell Proliferation
Pharmacology
Neoplasm Metastasis
Survival
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pancreatic cancer-Associated retinoblastoma 1 dysfunction enables TGF-?beta;?to promote proliferation. / Jesse Gore, A.; Deitz, Samantha L.; Palam, Lakshmi Reddy; Craven, Kelly E.; Korc, Murray.

In: Journal of Clinical Investigation, Vol. 124, No. 1, 02.01.2014, p. 338-352.

Research output: Contribution to journalArticle

Jesse Gore, A. ; Deitz, Samantha L. ; Palam, Lakshmi Reddy ; Craven, Kelly E. ; Korc, Murray. / Pancreatic cancer-Associated retinoblastoma 1 dysfunction enables TGF-?beta;?to promote proliferation. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 1. pp. 338-352.
@article{3ef069ce00654672957ff79ede9b9090,
title = "Pancreatic cancer-Associated retinoblastoma 1 dysfunction enables TGF-?beta;?to promote proliferation",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is often associated with overexpression of TGF-?. Given its tumor suppressor functions, it is unclear whether TGF-is a valid therapeutic target for PDAC. Here, we found that proliferating pancreatic cancer cells (PCCs) from human PDAC patients and multiple murine models of PDAC (mPDAC) often exhibit abundant levels of phosphorylated retinoblastoma 1 (RB) and Smad2. TGF-?1 treatment enhanced proliferation of PCCs isolated from KrasG12D-driven mPDAC that lacked RB (KRC cells). This mitogenic effect was abrogated by pharmacological inhibition of type I TGF-receptor kinase, combined inhibition of MEK/Src or MEK/PI3K, and restoration of RB expression. TGF-?1 promoted epithelial-to-mesenchymal transition (EMT), invasion, Smad2/3 phosphorylation, Src activation, Wnt reporter activity, and Smad-dependent upregulation of Wnt7b in KRC cells. Importantly, TGF-?1-induced mitogenesis was markedly attenuated by inhibition of Wnt secretion. In an in vivo syngeneic orthotopic model, inhibition of TGF-signaling suppressed KRC cell proliferation, tumor growth, stroma formation, EMT, metastasis, ascites formation, and Wnt7b expression, and markedly prolonged survival. Together, these data indicate that RB dysfunction converts TGF-to a mitogen that activates known oncogenic signaling pathways and upregulates Wnt7b, which synergize to promote PCC invasion, survival, and mitogenesis. Furthermore, this study suggests that concomitantly targeting TGF-And Wnt7b signaling in PDAC may disrupt these aberrant pathways, which warrants further evaluation in preclinical models.",
author = "{Jesse Gore}, A. and Deitz, {Samantha L.} and Palam, {Lakshmi Reddy} and Craven, {Kelly E.} and Murray Korc",
year = "2014",
month = "1",
day = "2",
doi = "10.1172/JCI71526",
language = "English",
volume = "124",
pages = "338--352",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Pancreatic cancer-Associated retinoblastoma 1 dysfunction enables TGF-?beta;?to promote proliferation

AU - Jesse Gore, A.

AU - Deitz, Samantha L.

AU - Palam, Lakshmi Reddy

AU - Craven, Kelly E.

AU - Korc, Murray

PY - 2014/1/2

Y1 - 2014/1/2

N2 - Pancreatic ductal adenocarcinoma (PDAC) is often associated with overexpression of TGF-?. Given its tumor suppressor functions, it is unclear whether TGF-is a valid therapeutic target for PDAC. Here, we found that proliferating pancreatic cancer cells (PCCs) from human PDAC patients and multiple murine models of PDAC (mPDAC) often exhibit abundant levels of phosphorylated retinoblastoma 1 (RB) and Smad2. TGF-?1 treatment enhanced proliferation of PCCs isolated from KrasG12D-driven mPDAC that lacked RB (KRC cells). This mitogenic effect was abrogated by pharmacological inhibition of type I TGF-receptor kinase, combined inhibition of MEK/Src or MEK/PI3K, and restoration of RB expression. TGF-?1 promoted epithelial-to-mesenchymal transition (EMT), invasion, Smad2/3 phosphorylation, Src activation, Wnt reporter activity, and Smad-dependent upregulation of Wnt7b in KRC cells. Importantly, TGF-?1-induced mitogenesis was markedly attenuated by inhibition of Wnt secretion. In an in vivo syngeneic orthotopic model, inhibition of TGF-signaling suppressed KRC cell proliferation, tumor growth, stroma formation, EMT, metastasis, ascites formation, and Wnt7b expression, and markedly prolonged survival. Together, these data indicate that RB dysfunction converts TGF-to a mitogen that activates known oncogenic signaling pathways and upregulates Wnt7b, which synergize to promote PCC invasion, survival, and mitogenesis. Furthermore, this study suggests that concomitantly targeting TGF-And Wnt7b signaling in PDAC may disrupt these aberrant pathways, which warrants further evaluation in preclinical models.

AB - Pancreatic ductal adenocarcinoma (PDAC) is often associated with overexpression of TGF-?. Given its tumor suppressor functions, it is unclear whether TGF-is a valid therapeutic target for PDAC. Here, we found that proliferating pancreatic cancer cells (PCCs) from human PDAC patients and multiple murine models of PDAC (mPDAC) often exhibit abundant levels of phosphorylated retinoblastoma 1 (RB) and Smad2. TGF-?1 treatment enhanced proliferation of PCCs isolated from KrasG12D-driven mPDAC that lacked RB (KRC cells). This mitogenic effect was abrogated by pharmacological inhibition of type I TGF-receptor kinase, combined inhibition of MEK/Src or MEK/PI3K, and restoration of RB expression. TGF-?1 promoted epithelial-to-mesenchymal transition (EMT), invasion, Smad2/3 phosphorylation, Src activation, Wnt reporter activity, and Smad-dependent upregulation of Wnt7b in KRC cells. Importantly, TGF-?1-induced mitogenesis was markedly attenuated by inhibition of Wnt secretion. In an in vivo syngeneic orthotopic model, inhibition of TGF-signaling suppressed KRC cell proliferation, tumor growth, stroma formation, EMT, metastasis, ascites formation, and Wnt7b expression, and markedly prolonged survival. Together, these data indicate that RB dysfunction converts TGF-to a mitogen that activates known oncogenic signaling pathways and upregulates Wnt7b, which synergize to promote PCC invasion, survival, and mitogenesis. Furthermore, this study suggests that concomitantly targeting TGF-And Wnt7b signaling in PDAC may disrupt these aberrant pathways, which warrants further evaluation in preclinical models.

UR - http://www.scopus.com/inward/record.url?scp=84892912591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892912591&partnerID=8YFLogxK

U2 - 10.1172/JCI71526

DO - 10.1172/JCI71526

M3 - Article

VL - 124

SP - 338

EP - 352

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -